Payment overview · 2025
General Payments
$28,226.56
62 reported records · 13 companies
Healthcare provider profile · identity verified
Shane Paul Prejean, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Advanced Heart Failure and Transplant Cardiology · HOUMA, LA · NPI 1609141985
Verified facts
What the public records show
CMS Open Payments records show Shane Paul Prejean, M.D. received $28,226.56 in general payments during 2025 across 62 reported records.
Novo Nordisk Inc accounted for 80.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Camzyos, Jardiance, Wegovy.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAMZYOS as an associated drug or biological on 41009 records involving 16400 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Camzyos by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 499 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 499 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYNDAMAX as an associated drug or biological on 1880 records involving 1527 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vyndamax by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22,820.43 | 80.8% | 11 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,936.56 | 6.9% | 18 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $1,737.36 | 6.2% | 10 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$1,295.31 | 4.6% | 9 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $157.55 | 0.6% | 5 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $99.18 | 0.3% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $47.32 | 0.2% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $34.61 | 0.1% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $25.49 | 0.1% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $23.34 | 0.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.49 | 0.1% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $14.97 | 0.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.95 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,156.25 | 7 |
| Travel and Lodging | $2,599.08 | 12 |
| Food and Beverage | $2,471.23 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22,820.43 | 11 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $1,904.44 | 17 | 2025 |
Source payment records
|
|||||
| EVOQUE Normalized: evoque |
Device | Edwards Lifesciences Corporation | $1,737.36 | 10 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $1,271.06 | 8 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $157.55 | 5 | 2025 |
Source payment records
|
|||||
| ANGIOVAC Normalized: angiovac |
Device | AngioDynamics, Inc. | $99.18 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $47.32 | 2 | 2025 |
Source payment records
|
|||||
| AMPLATZER TALISMAN Normalized: amplatzer talisman |
Device | Abbott Laboratories | $32.12 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $25.49 | 1 | 2025 |
Source payment records
|
|||||
| SPIDERFX Normalized: spiderfx |
Device | Medtronic, Inc. | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| TUBING KIT - STROKE Normalized: tubing kit stroke |
Device | Terumo Medical Corporation | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAMZYOS camzyos |
2025 | Camzyos | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 223 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
223 | 54 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | CAMZYOS open payments reported associated product |
CMS Open Payments — General Payments 41009 supporting records · 16400 recipient NPIs · example record 1184377697 |
Camzyos · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
499 | 110 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
138 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
499 | 110 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | VYNDAMAX open payments reported associated product |
CMS Open Payments — General Payments 1880 supporting records · 1527 recipient NPIs · example record 1228795749 |
Vyndamax · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1220 | 360 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1025 | 276 |
| Metoprolol Succinate | Metoprolol Succinate | 966 | 289 |
| Amlodipine Besylate | Amlodipine Besylate | 719 | 184 |
| Clopidogrel | Clopidogrel Bisulfate | 637 | 190 |
| Furosemide | Furosemide | 543 | 169 |
| Eliquis | Apixaban | 499 | 110 |
| Losartan Potassium | Losartan Potassium | 455 | 132 |
| Carvedilol | Carvedilol | 407 | 102 |
| Ezetimibe | Ezetimibe | 378 | 126 |
| Lisinopril | Lisinopril | 339 | 95 |
| Pravastatin Sodium | Pravastatin Sodium | 272 | 72 |
| Spironolactone | Spironolactone | 271 | 82 |
| Metoprolol Tartrate | Metoprolol Tartrate | 258 | 73 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 247 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 225 | 71 |
| Jardiance | Empagliflozin | 223 | 54 |
| Valsartan | Valsartan | 208 | 57 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 198 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 186 | 50 |
| Doxazosin Mesylate | Doxazosin Mesylate | 166 | 43 |
| Torsemide | Torsemide | 151 | 49 |
| Entresto | Sacubitril/Valsartan | 138 | 38 |
| Ozempic | Semaglutide | 138 | 22 |
| Potassium Chloride | Potassium Chloride | 138 | 42 |
| Amiodarone Hcl | Amiodarone Hcl | 125 | 46 |
| Repatha Sureclick | Evolocumab | 120 | 27 |
| Nitroglycerin | Nitroglycerin | 112 | 67 |
| Irbesartan | Irbesartan | 89 | 22 |
| Mupirocin | Mupirocin | 89 | 84 |
| Enalapril Maleate | Enalapril Maleate | 87 | 21 |
| Ranolazine Er | Ranolazine | 86 | 16 |
| Nifedipine Er | Nifedipine | 75 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 21 |
| Metolazone | Metolazone | 68 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 20 |
| Xarelto | Rivaroxaban | 63 | 17 |
| Warfarin Sodium | Warfarin Sodium | 61 | 22 |
| Telmisartan | Telmisartan | 56 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | 17 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 50 | 14 |
| Atenolol | Atenolol | 49 | 15 |
| Simvastatin | Simvastatin | 49 | 11 |
| Repatha Pushtronex | Evolocumab | 48 | 17 |
| Omeprazole | Omeprazole | 47 | 11 |
| Levothyroxine Sodium | Levothyroxine Sodium | 46 | 14 |
| Chlorthalidone | Chlorthalidone | 45 | 12 |
| Digoxin | Digoxin | 44 | 11 |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Ramipril | Ramipril | 36 | 11 |
| Metformin Hcl | Metformin Hcl | 35 | suppressed |
| Cilostazol | Cilostazol | 34 | 13 |
| Brilinta | Ticagrelor | 33 | 16 |
| Sotalol | Sotalol Hcl | 33 | 11 |
| Alprazolam | Alprazolam | 32 | 22 |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Gabapentin | Gabapentin | 26 | 11 |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Camzyos | Mavacamten | 23 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 23 | suppressed |
| Nexletol | Bempedoic Acid | 23 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 22 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Eplerenone | Eplerenone | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Wegovy | Semaglutide | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Vyndamax | Tafamidis | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $28,226.56 · 62 records | Novo Nordisk Inc | AFREZZA, AMPLATZER TALISMAN, ANGIOVAC, Assure WCD, CAMZYOS, COREVALVE EVOLUT R, CT THROMBECTOMY SYSTEM KIT, EVOQUE, FLOWTRIEVER CATHETER, S, JARDIANCE, SPIDERFX, TRICLIP, TUBING KIT - STROKE, VYNDAQEL, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Camzyos play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error